Newsletter Subscribe
Enter your email address below and subscribe to our newsletter
Treatment
Share your love
Oluwatosin U. Smith, MD, previews a program of collaborative care and practical learning
Educational committee member Oluwatosin U. Smith, MD, highlights the 2025 Ophthalmology Times EyeCon® and Optometry Times EyeCon® conference, a multispecialty meeting for ophthalmologists and optometrists, highlighting program updates, collaborative learning opportunities, and evolving approaches in patient care. To learn more…
Boehringer Ingelheim and Palatin Technologies enter into a global research collaboration and licensing agreement
(Image Credit: AdobeStock/Vittaya_25) Boehringer Ingelheim and Palatin Technologies have entered into a global research collaboration and licensing agreement to develop a potential first-in-class melanocortin receptor-targeted treatment for patients with retinal diseases. Under the terms of the agreement, Palatin will receive…
Infographic: landmark trials in neuro-ophthalmology—results of the Idiopathic Intracranial Hypertension Treatment Trial (IIHTT) | Eye – Nature
Infographic: landmark trials in neuro-ophthalmology—results of the Idiopathic Intracranial Hypertension Treatment Trial (IIHTT) | Eye Nature Source: Author: | Date: 2025-07-04 07:00:00 Source: Author: | Date: 2025-07-04 07:00:00
New research uncovers promising treatment for neurodegenerative diseases like ALS, glaucoma | Ophthalmology – Stanford Medicine
New research uncovers promising treatment for neurodegenerative diseases like ALS, glaucoma | Ophthalmology Stanford Medicine Source: Author: | Date: 2025-02-20 08:00:00 Source: Author: | Date: 2025-02-20 08:00:00
Peptide Eye Drops Offer Hope for Dry AMD
Researchers from the Natural Product Drug Development Center at the Korea Institute of Science and Technology (KIST), led by Dr. Moon-Hyeong Seo, have developed an innovative therapeutic agent for dry age-related macular degeneration (AMD) in the form of peptide-based eye…
MicroPulse TLT Proven Effective for Glaucoma
Iridex Corporation, a global leader in laser-based medical systems for glaucoma and retinal disease treatment, has announced the publication of a groundbreaking peer-reviewed study in Ophthalmology Therapy. The study provides compelling evidence of the long-term safety and efficacy of MicroPulse…
Galimedix Begins Phase 2 Trial for GAL-101 in Dry AMD
Galimedix Therapeutics has announced the initiation of a phase 2 clinical study called eDREAM (NCT06659549), evaluating the efficacy and safety of GAL-101 eye drops in patients with dry age-related macular degeneration (AMD) and geographic atrophy (GA). About the Phase 2…
Glaukos Submits FDA Application for Epioxa Therapy
Glaukos Corporation has officially submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for its innovative corneal cross-linking therapy, Epioxa (Epi-on). This next-generation treatment is designed for patients with keratoconus and represents a significant advancement…
4DMT Reveals Preclinical Data on TVE Platform
4D Molecular Therapeutics (4DMT) has announced the publication of preclinical data underscoring the capabilities of its Therapeutic Vector Evolution (TVE) platform. The research focuses on the intravitreal R100 vector and the R100-based genetic medicine 4D-150. This groundbreaking study, titled “Design…
Sepul Bio Launches Ultevursen Phase 2b Trial for RP
Sepul Bio has announced the dosing of the first patient in the LUNA clinical study, a Phase 2b trial evaluating ultevursen for the treatment of USH2A-associated retinitis pigmentosa (RP). This milestone represents renewed hope for individuals affected by this debilitating…